AU Patent

AU2022291504B2 — Substituted tricyclic compounds as fgfr inhibitors

Assigned to Incyte Holdings Corp · Expires 2024-08-01 · 2y expired

What this patent protects

The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.

USPTO Abstract

The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022291504B2
Jurisdiction
AU
Classification
—
Expires
2024-08-01
Drug substance claim
No
Drug product claim
No
Assignee
Incyte Holdings Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.